Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at University of Chicago Medicine

Sites in Chicago, IL

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1114
Shown on this page
12
Current sort
Recently updated
Campus scope
University of Chicago Medicine, Chicago, IL
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within University of Chicago Medicine, Chicago, IL. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 829–840 of 1,114 matching trials with a site at University of Chicago Medicine, Chicago, IL.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Not applicable Interventional

TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention

NCT04294927
Status at this site: Recruiting
View directory record Official record
Conditions
BRCA1 Gene Mutation, BRCA2 Gene Mutation, RAD51C Gene Mutation, RAD51D Gene Mutation, BRIP1 Gene Mutation, Ovarian Cancer
Interventions
Risk-reducing salpingectomy with delayed oophorectomy, Risk-reducing salpingo-oophorectomy
Procedure
Lead sponsor
University Medical Center Nijmegen
Other
Eligibility
25 Years to 50 Years · Female only
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2040
U.S. locations
11
States / cities
Chicago, Illinois • Boston, Massachusetts • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Nov 5, 2026, 6:28 AM EST
Active, not recruiting Not applicable Interventional

Study to Assess for Measurable Residual Disease (MRD) in Multiple Myeloma Patients

NCT04108624
Site status not listed — check the official record
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Screening Phase, Discontinuation Phase
Other · Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Nov 5, 2026, 6:28 AM EST
Recruiting Phase 2Phase 3 Interventional

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

NCT06581406
Status at this site: Recruiting
View directory record Official record
Conditions
Metastatic Uveal Melanoma
Interventions
RP2, Ipilimumab, Nivolumab
Biological
Lead sponsor
Replimune, Inc.
Industry
Eligibility
Not listed
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
29
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Nov 5, 2026, 6:28 AM EST
Active, not recruiting Not applicable Interventional

Single-incision Versus Retropubic Mid-Urethral Sling (Solyx) for SUI During Minimally Invasive Sacrocolpopexy

NCT04586166
Site status not listed — check the official record
View directory record Official record
Conditions
Stress Urinary Incontinence, Pelvic Floor Disorders
Interventions
RP Sling, SIS
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years and older · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2032
U.S. locations
5
States / cities
Coconut Creek, Florida • Augusta, Georgia • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Nov 5, 2026, 6:28 AM EST
Recruiting Phase 1Phase 2 Interventional

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

NCT04665206
Status at this site: Recruiting
View directory record Official record
Conditions
Solid Tumor, Adult, Mesothelioma, NSCLC
Interventions
VT3989, Nivolumab & Ipilimumab, Osimertinib, Pemetrexed/Carboplatin
Drug
Lead sponsor
Vivace Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
9
States / cities
San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Nov 5, 2026, 6:28 AM EST
Recruiting Not applicable Interventional

Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women

NCT04124120
Status at this site: Recruiting
View directory record Official record
Conditions
Heart Diseases, Coronary Artery Disease, Coronary Artery Bypass Grafting
Interventions
Single arterial graft, Multiple arterial grafting
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Female only
Enrollment
2,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
42
States / cities
Los Angeles, California • Pomona, California • San Francisco, California + 36 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Nov 5, 2026, 6:28 AM EST
Recruiting Phase 1Phase 2 Interventional

A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

NCT04486352
Status at this site: Active, not recruiting
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Atezolizumab - 28 Day Cycle, Bevacizumab, Ipatasertib, Talazoparib, Trastuzumab emtansine, Tiragolumab, Atezolizumab - 21 Day Cycle, Inavolisib, Letrozole, Giredestrant, Abemaciclib
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older · Female only
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
21
States / cities
Duarte, California • San Francisco, California • Washington D.C., District of Columbia + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Nov 5, 2026, 6:28 AM EST
Recruiting Phase 1 Interventional

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)

NCT05862012
Status at this site: Recruiting
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
ISB 2001
Drug
Lead sponsor
Ichnos Sciences SA
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
10
States / cities
Palo Alto, California • Miami, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Nov 5, 2026, 6:28 AM EST
Active, not recruiting Phase 4 Interventional

US IDE Study of the Contour NEurovasCular System™ for IntraCranial Aneurysm Repair

NCT04852783
Site status not listed — check the official record
View directory record Official record
Conditions
Aneurysm, Intracranial
Interventions
Contour Neurovascular System
Device
Lead sponsor
Cerus Endovascular, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
20
States / cities
Englewood, Colorado • Jacksonville, Florida • Chicago, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Nov 5, 2026, 6:28 AM EST
Recruiting Phase 1 Interventional

Hypofractionation (Radiation) Trial for Multiple Myeloma

NCT06270888
Status at this site: Recruiting
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Radiation
Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Nov 5, 2026, 6:28 AM EST
Active, not recruiting Phase 2 Interventional

Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita

NCT01659606
Site status not listed — check the official record
View directory record Official record
Conditions
Dyskeratosis Congenita, Hoyeraal Hreidarsson Syndrome, Revesz Syndrome, Aplastic Anemia
Interventions
alemtuzumab, Fludarabine, Cyclosporins, Mycophenolate mofetil, Tacrolimus
Biological · Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
30 Days to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2034
U.S. locations
11
States / cities
Chicago, Illinois • Boston, Massachusetts • Kansas City, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Nov 5, 2026, 6:28 AM EST
Recruiting Phase 1Phase 2 Interventional

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

NCT06395519
Status at this site: Recruiting
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Epithelial Ovarian Cancer, BRCA2 Mutation, ER+ Breast Cancer, Castrate Resistant Prostate Cancer, BRCA1 Mutation, BRCA Mutation, Endometrial Cancer, Colorectal Cancer, Gastric Cancer
Interventions
ETX-19477
Drug
Lead sponsor
858 Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
14
States / cities
Phoenix, Arizona • New Haven, Connecticut • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Nov 5, 2026, 6:28 AM EST

About this University of Chicago Medicine institution page

What this page lists
ClinicalTrials.gov records that list University of Chicago Medicine in Chicago, IL as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.